Isabel Muehlen-Bartmer

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Matthew C. Riddle, Geremia B. Bolli, M. Ziemen et al. · Diabetes Care · 2014 · 360 citations

Medicine, Endocrinology, Pharmacotherapy +17

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Hannele Yki‐Järvinen, Richard M. Bergenstal, M. Ziemen et al. · Diabetes Care · 2014 · 274 citations

Medicine, Endocrinology, Pharmacotherapy +17

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( <scp>GetGoal</scp> ‐P)

M. Pinget, Ronald Goldenberg, Elisabeth Niemoeller et al. · Diabetes Obesity and Metabolism · 2013 · 137 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension

H Yki-Järvinen, Richard M. Bergenstal, Geremia B. Bolli et al. · Diabetes Obesity and Metabolism · 2015 · 131 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)

Julio Rosenstock, M Hanefeld, Paramesh Shamanna et al. · Journal of Diabetes and its Complications · 2014 · 126 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13